TFSeB
TFSeB is an orally active neuroprotective agent. TFSeB can reduce Streptozotocin (STZ) (HY-13753) induced MAO-B and AChE activity. TFSeB exerts neuroprotective effects by increasing the expression of BCL-2, BDNF, NRF2, and decreasing the expression of BAX. TFSeB can reduce lipid peroxidation (TBARS) and reactive oxygen species (ROS) levels. TFSeB can reduce neuroinflammation. TFSeB can be used for research on Alzheimer’s disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3017240-62-6
- Fòrmula: C16H13F3OSe
- Peso molecular:357.23
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
|
Bcl-2 |
AChE |
Bax |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Swiss mice (25-35 g) received intracerebroventricular injections of Streptozotocin (STZ) (HY-13753) (3 mg/kg)[1]
-
Dosage:1 mg/kg or 5 mg/kg
-
Administration:Oral gavage (i.g.); once daily for 20 days
-
Result:Significantly improved STZ-induced spatial working memory deficits.
Restored short-term and long-term recognition memory in the mice with an Alzheimer’s disease.
Significantly reduced MAO-B activity as a MAO-B modulator.
Significantly reversed AChE activity in the STZ mice.
Improved oxidative stress levels, including a reduction in TBARS, ROS, NOx, and NPSH levels.
Upregulated the levels of BDNF, NRF2 and BCL-2 and downregulated the levels of NF-κB, IL-6, CAT, SOD, GSk3B and BAX.
Did not cause liver, kidney toxicity or metabolic abnormalities.
Chemical Information
-
No. CAS 3017240-62-6
-
Peso molecular 357.23
-
Fòrmula C16H13F3OSe
-
SMILES
FC(F)(C1=CC=CC([Se]CC2CC3=C(O2)C=CC=C3)=C1)F
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)